HE4 and mesothelin: Novel biomarkers of ovarian carcinoma in patients with pelvic masses

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 111-116

  Abdel Azeez, Hala A ^a   Labib, Hany A ^a   Sharaf, Samar M ^a   Refaie, Ashraf N ^b  

^a Zagazig University   (Egypt)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

CA 125; HE4; Mesothelin; Ovarian cancer; Pelvic mass; Tumor markers

Indexed keywords

BETA DEFENSIN; CA 125 ANTIGEN; DEFB126 PROTEIN, HUMAN; EPIDIDYMAL SECRETORY PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN; MESOTHELIN; TUMOR MARKER;

BLOOD; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PELVIS TUMOR; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA, MUCINOUS; BETA-DEFENSINS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; GPI-LINKED PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77955834079     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Badgwell D, Lu Z, Cole L, et al (2007). Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol, 106, 490-7.
2. Bast Jr RC, Klug TL, St John E, et al (1983). A radio-immunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309, 883-7.
3. Censullo P, Davitz MA (1994). How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membrane. Semin Immunol, 6, 81-8.
4. Chang K, Pastan I, Willingham M (1992). Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer, 51, 548-54.
5. Chang K, Pastan I (1996). Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA, 93, 136-40.
6. Cole LA, Nam JH (1989). Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer. Yale J Biol Med, 62, 367-78.
7. DePriest PD, Van Jr NJ, Gallion HH, et al (1993). Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol, 51, 205-9.
8. Eagle K, Ledermann JA (1997). Tumor markers in ovarian malignancies. Oncologist, 2, 324-9.
9. Einhorn N (1992). Ovarian cancer. Early diagnosis and screening. Hematol Oncol Clin North Am, 6, 843-50.
10. Hassan R, Bera T, Pastan I (2004). Mesothelin: a new target for immunotherapy. Clin Cancer Res, 10, 3937-42.
11. Hassan R, Alan T, Remaley AT, et al (2006). Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res, 12, 447-53.
12. Havrilesky LJ, Whitehead CM, Rubatt JM, et al (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol, 110, 374-82.
13. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 63, 3695-700.
14. Hising C, Anjegard IM, Einhorn N (1991). Clinical relevance of the CA125 assay in monitoring of ovarian cancer patients. Am J Clin Oncol, 14, 111-4.
15. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
16. Kojima T, Oh-eda M, Hattori K, et al (1995). Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem, 270, 21984-90.
17. McIntosh MW, Drescher C, Karlan B, et al (2004). Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol, 95, 9-15.
18. Moore RG, Brown AK, Miller MC, et al (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 108, 402-8.
19. Moore RG, McMeekin DS, Brown AK, et al (2009). A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112, 40-6.
20. Nagele F, Petru E, Medl M, et al (1995). Preoperative CA125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol, 86, 259-64.
21. Palmer C, Pratt J, Basu B, Helena E (2006). A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference. Gynecol Oncol, 101, 4-11.
22. Robinson BS, Creaney J, Lake R, et al (2003). Mesothelin-family proteins and diagnosis of mesothelioma. Lancet, 362, 1612-6.
23. Rump A, Morikawa Y, Tanaka M, et al (2003). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem, 279, 9190-8.
24. Schink JC (1999). Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Sem Oncol, 26 (Suppl 1), 2-7.
25. Scholler N, Fu N,Yang Y, et al (1999). Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA, 96, 11531-6.
26. Scholler N, Crawford M, Sato A, et al (2006). Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res, 12, 2117-24.
27. Zurawski VR, Knapp RC, Einhorn N, et al (1988). An initial analysis of preoperative serum CA125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol, 30, 7-14.